The United Kingdom and the United States have reached a significant trade agreement that will keep no levies on British medicine shipments going into the US market.
The Terms of the Accord
As part of the deal, the UK has pledged to increase expenditure on pharmaceuticals through the NHS. This move secures that duties on these key products will be held at zero for a timeframe of 36 months.
This deal comes after recent statements to dramatically increase tariffs on patented drug imports, with increases discussed reaching 100%.
"This agreement with the United Kingdom bolsters the international landscape for cutting-edge drugs and establishes much-needed fairness to U.S.–U.K. medicine commerce," a statement noted.
Commercial Significance
Drugs constitute one of the Britain's biggest export categories to the United States, which is clearly the biggest market for major UK drugmakers.
Trade data show that in the year leading up to the third quarter, the UK shipped drugs worth billions to the US. This amount made up a significant portion of total UK exports in that timeframe.
"This deal protects employment, stimulates funding and paves the way for the UK to become a international leader for medical research," the Business and Trade Secretary remarked.
Key NHS Changes
The pact involves several specific commitments from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a goal to raise overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount drug companies must return to the NHS to control costs will be capped at fifteen percent. In the past, repayments exceeded twenty percent.
Broader Context
The deal takes place against a protracted row between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
These tensions were exacerbated by arguments that American consumers were paying significantly more for the identical medicines than patients in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been delayed or cancelled, while substantial investments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
